logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Muscular Dystrophy Duchenne

    FiltersReset Filters
    7 results

    • amondys 45

      (casimersen)
      Sarepta Therapeutics, Inc.
      Usage: AMONDYS 45 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene suitable for exon 45 skipping. Its approval is based on increased dystrophin production in skeletal muscle, with continued approval dependent on confirmatory trial results.

    • deflazacort

      (Deflazacort)
      Sun Pharmaceutical Industries Limited
      Usage: Deflazacort tablets are indicated for treating Duchenne muscular dystrophy (DMD) in patients aged 5 years and older. Additional pediatric information is available but not included on the label due to marketing exclusivity rights.

    • elevidys

      (delandistrogene moxeparvovec-rokl)
      Sarepta Therapeutics, Inc.
      Usage: ELEVIDYS is indicated for treating Duchenne muscular dystrophy (DMD) in individuals aged 4 and older, including both ambulatory patients with a confirmed DMD gene mutation and non-ambulatory patients. The latter indication is approved under accelerated provisions based on the expression of micro-dystrophin in skeletal muscle.

    • emflaza

      (deflazacort)
      PTC Therapeutics, Inc.
      Usage: EMFLAZA is indicated for treating Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.

    • exondys 51

      (eteplirsen)
      Sarepta Therapeutics, Inc.
      Usage: EXONDYS 51 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene suitable for exon 51 skipping. Its approval is based on observed increases in dystrophin in skeletal muscle, pending further verification of clinical benefit in ongoing trials.

    • viltepso

      (viltolarsen)
      NS Pharma, Inc.
      Usage: VILTEPSO is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation suitable for exon 53 skipping. Approval is based on increased dystrophin production in skeletal muscle, with continued approval dependent on further verification of clinical benefits.

    • vyondys 53

      (golodirsen)
      Sarepta Therapeutics, Inc.
      Usage: VYONDYS 53 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation suitable for exon 53 skipping. Approval is based on increased dystrophin production in skeletal muscle, with continued approval dependent on clinical benefit verification in further trials.